Intranasal metoclopramide

Drugs

Volumn 58, Issue 2, 1999, Pages 315-322

  Ormrod, Douglas ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; DEXAMETHASONE; METOCLOPRAMIDE;

AREA UNDER THE CURVE; CLINICAL TRIAL; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONCENTRATION; DRUG DOSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPEPSIA; EPISTAXIS; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NOSE IRRITATION; NOSE MUCOSA; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOECONOMICS; POSTOPERATIVE CARE; REVIEW; TASTE DISORDER; VOMITING;

ADMINISTRATION, INTRANASAL; ANTIEMETICS; CLINICAL TRIALS; HUMANS; METOCLOPRAMIDE;

EMESIS;

EID: 0032808225     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958020-00012     Document Type: Review

References (27)

1. 1. Italian Group for Antiemetic Research. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. J Clin Oncol 1997; 15 (1): 124-30
2. 2. American Society of Health-System Pharmacists. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health System Pharm 1999; 56: 729-64
3. 3. Roila F, Ballatori E. The efficacy and cost-effectiveness of various antiemetic regimens. Curr Opin Oncol 1998 Jul; 10: 310-5
4. 4. Grunberg SM. Cost-effective use of antiemetics. Oncology Huntingl 1998 Mar; 12 (3) Suppl. 4: 38-42
5. 5. Citron ML, Reynolds JR, Kalra J, et al. Pharmacokinetic comparison of intranasal, oral, and intramuscular metoclopramide in healthy volunteers. Cancer Treat Rep 1987; 71 (3): 317-9
6. 6. Ward MJ, Buss DC, Eltershaw J, et al. Bioavailability of intranasal metoclopramide. Br J Clin Pharmacol 1989 Nov; 28: 616-8
7. 7. Scaglione F, Scanni A, Tomirotti M, et al. Pharmacokinetics and bioavailability of metoclopramide nasal spray versus metoclopramide intravenous in healthy volunteers and cancer patients. Arzneimittel Forschung 1993 Sep; 43 (11): 986-8
8. 8. Harrington RA, Hamilton CW, Brogden JA, et al. Metoclopramide. An updated review of its pharmacological properties and clinical use. Drugs 1983; 25 (5): 451-94
9. 9. Mitchelson F. Pharmacologic agents affecting emesis: a review (part I). Drugs 1992; 43 (3): 295-315
10. 10. Fozard JR, Mobarok Ali AT. Blockade of neuronal tryptamine receptors by metoclopramide. Eur J Pharmacol 1978; 49: 109-12
11. 11. Ettinger DS. Preventing chemotherapy-induced nausea and vomiting: an update and a review of emesis. Semin Oncol 1995 Aug; 22 Suppl. 10: 6-18
12. 12. Gralla RJ. A double-blind multiple dose study of the efficacy and safety of 20mg, 40mg and 80mg of intranasal metoclopramide compared to placebo in cancer patients treated with emetogenic chemotherapeutic agents. Crinos Industria Farmacobiologica S.p.A., Como, Italy, 1993, Report no. U-90-01. (Data on file)
13. 13. Weber W, Pabst G, Dilger C, et al. Pharmacokinetics/Bioavailability evaluation of four metoclopramide preparations in 28 health volunteers. Naska Pharmacal Inc./RiboGene Inc., Hayward CA, USA, 1991, Protocol no. 90762. (Data on file)
14. 14. Kris MG, Gralla RJ, Clark RA, et al. Incidence, course and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985; 3 (10): 1379-84
15. 15. Tavorath R, Hesketh PJ. Drug treatment of chemotherapy-induced delayed emesis. Drugs 1996 Nov; 52 (5): 639-48
16. 16. DeMulder PHM, Seynaeve C, Vermorken JB, et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 1990; 113: 834-40
17. 17. Tomirotti M, Dimaiuta M, Confalonieri M, et al. Efficacy and tolerability of nasalty administered compared to parenterally administered metoclopramide in the symptomatic treatment of chemotherapy-induced emesis in cancer outpatients: a controlled clinical study. Support Care Cancer 1994 Nov; 2: 389-92
18. 18. Eckhardt S, Ady N, Baki M, et al. A double-blind multiple dose parallel arm comparison of the antiemetic and antinausea efficacy and safety of 20mg and 40mg intranasal metoclopramide compared to placebo in cancer patients treated with emetogenic chemotherapeutic agents, a phase III clinical trial. Crinos Industria Farmacobiologica S.p.A., Como, Italy, 1991. Report no. U-90-02/A, (Data on file)
19. 19. Bodrogi I, Baki M, Horti J, et al. A double-blind multiple dose parallel arm study of the antiemetic and antinausea efficay and safety of 20mg and 40mg intranasal metoclopramide compared to placebo in cancer patients treated with emetogenic chemotherapeutic agents. Crinos Industria Farmacobilogica S.p.A., Como, Italy, 1992. Report no. U-91-02BH. (Data on file)
20. 20. Chiara S, Campora E, Rosso R. Controllo dell'emesi tardiva; studio randomizzato di confronto metoclopramide spray nasale + desametasone versus metoclopramide compresse + desametasone in pazienti riceventi chemioterapia a moderato potere emetizzante. Crinos Industria Farmacobiologica S.p.A., Como Italy, 1994. Protocol no. MCP 02/92. (Data on file)
21. 21. Chiara S, Campora E, Simoni C, et al. Prevention of delayed emesis with metoclopramide and dexamethasone in patients receiving moderately emetogenic cytotoxic treatment. Anticancer Res 1995; 15: 1597-600
22. 22. Locatelli MC, Pessi A, D'Antona A, et al. Tolerability and safety of nasally administered metoclopramide for the prevention of cis-platinum (CDDP)induced delayed emesis [abstract]. Proc Am Soc Clin Oncol 1995 Mar; 14: 533
23. 23. Locatelli C, D'Antona A. Metoclopramide nasal spray in the prevention of delayed hyperemsis in neoplastic patients under cisplatin chemotherapy: uncontrolled pilot study. Crinos Industria Farmacobiologica S.p.A, Como, Italy, 1997. Protocol no. MCP 01/92. (Data on file)
24. 24. Lin DM, Furst SR, Rodarte A. A double-blind comparison of metoclopramide and droperidol for prevention of emesis following strabismus surgery. Anesthesiology 1992; 76: 357-61
25. 25. Wagner BKJ, Berman SL, Devitt PA, et al. A double-blind, placebo-controlled evaluation of intranasal metoclopramide in the prevention of postoperative nausea and vomiting. Pharmacotherapy 1996 Nov-Dec; 16 (6): 1063-9
26. 26. Battito M, Khairallah P, Conroy J, et al. A double-blind, dose-finding study to assess the safely and efficacy of intranasal metoclopramide vs placebo in the treatment of postoperative nausea or vomiting. Crinos Industria Farmacobiologica S.p.A., Como, Italy, 1992. Protocol no. U-90-04A. (Data on file)
27. 27. Bortoli A, Prada A, Confalonieri M, et al. Efficacy and tolerability of metoclopramide nasal spray in the symptomatic therapy of functional dyspepsia. Curr Ther Res 1994; 55: 1192-200